A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Breast Cancer Research and Treatment

Volumn 161, Issue 1, 2017, Pages 63-72

  Harbeck, Nadia ^a   Saupe, Steffen ^b   Jäger, Elke ^c   Schmidt, Marcus ^d   Kreienberg, Rolf ^e   Müller, Lothar ^f   Otremba, Burkhard Joerg ^g   Waldenmaier, Dirk ^h   Dorn, Julia ^b   Warm, Mathias ⁱ   Scholz, Michael ^j   Untch, Michael ^k   de Wit, Maike ^l   Barinoff, Jana ^m   Lück, Hans Joachim ^m   Harter, Philipp ⁿ   Augustin, Doris ^o   Harnett, Paul ^p   Beckmann, Matthias W ^q   Al Batran, Salah Eddin ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KRANKENHAUS NORDWEST   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f Onkologische Schwerpunktpraxis   (Germany)

^g Standort Oldenburg   (Germany)

^h MSD Sharp and Dohme GmbH   (Germany)

ⁱ Krankenhaus Holweide   (Germany)

^j TRIUM ANALYSIS ONLINE GMBH   (Germany)

^k HELIOS KLINIKUM BERLIN BUCH   (Germany)

^l VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^m DR HORST SCHMIDT KLINIKEN   (Germany)

ⁿ KLINIKEN ESSEN MITTE   (Germany)

^o Klinikum des Landkreises Deggendorf   (Germany)

^p Crown Princess Mary Cancer Centre Westmead   (Australia)

^q UNIVERSITY HOSPITAL ERLANGEN   (Germany)

more..

Author keywords

Capecitabine; Metastatic breast cancer; Pegylated liposomal doxorubicin; PELICAN

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOXORUBICIN; ANTINEOPLASTIC ANTIMETABOLITE; MACROGOL DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; EAR NOSE THROAT DISEASE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VOMITING; ANALOGS AND DERIVATIVES; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; DISEASE EXACERBATION; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CAPECITABINE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84992709496     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-4033-3     Document Type: Article

References (26)

1. Fountzilas G, Dafni U, Dimopoulos MA et al (2009) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115:87–99
2. Martín M, Ruiz A, Muñoz M et al (2007) Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8:219–225
3. Joensuu H, Holli K, Heikkinen M et al (1998) Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 16:3720–3730
4. Carrick S, Parker S, Thornton CE et al (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. doi:10.1002/14651858
5. Keller AM, Mennel RG, Georgoulias VA et al (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22:3893–3901
6. ®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–449
7. ®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86:1367–1372
8. O’Shaughnessy JA, Blum J, Moiseyenko V et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247–1254
9. Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493
10. National Comprehensive Cancer Network (2015) Clinical practice guidelines in oncology: breast cancer. Version 2.2015. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 11 Mar 2015
11. Hanf V, Schütz F, Liedtke C, Thill M (2014) AGO recommendations for the diagnosis and treatment of patients with advanced and metastatic breast cancer. Breast Care 9(3):202–209
12. Miwa M, Ura M, Nishida M et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281
13. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 92:205–216
14. Aaronson N, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:360–376
15. Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144
16. Bajetta E, Procopio G, Celio L et al (2005) Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23:2155–2161
17. Ranson MR, Carmichael J, O’Byrne K, Stewart S, Smith D, Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15:3185–3191
18. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037–1049
19. Yardley DA, Shipley DM, Greco FA et al (2004) Phase II randomized trial of pegylated liposomal doxorubicin vs. weekly docetaxel with subsequent crossover as first-line chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 88:S203
20. Huober J, Fett W, Nusch A et al (2010) A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer 10:2. doi:10.1186/1471-2407-10-2
21. Minea LN, Stanculeanu DL, Cringeanu A, Anghel RM (2004) Capecitabine monotherapy for elderly patients with metastatic breast cancer. J Clin Oncol 22(14):S797
22. Stockler MR, Harvey VJ, Francis PA et al (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29(34):4498–4504. doi:10.1200/JCO.2010.33.9101
23. El-Helw L, Coleman RE (2005) Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 14:368–374
24. Smorenburg CH, de Groot SM, van Leeuwen-Stok AE et al (2014) A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol 25(3):599–605
25. Hamaker ME, Seynaeve C, Wymenga AN et al (2014) Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists’ group. Breast 23:81–87
26. Kaufmann M, Maass N, Costa SD et al (2010) First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. Eur J Cancer 46:3184–3191